


## Larotinib

## Chemical Properties

CAS No. :	1438072-11-7
Formula:	C <sub>24</sub> H <sub>26</sub> ClFN <sub>4</sub> O <sub>4</sub>
Molecular Weight:	488.94
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC <sub>50</sub> of 0.6 nM for EGFR.
Targets(IC <sub>50</sub> )	EGFR,BTK,IRAK,Tyrosine Kinases
In vivo	Larotinib (250, 300, 350 mg; oral; once daily; patients) demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety. A phase 3 study is underway on 350 mg larotinib in ESCC patients with EGFR overexpression.[1]

## Solubility Information

Solubility	DMSO: 60 mg/mL (122.71 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--------------------------------------------------------------------------------------------------------------------------

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0452 mL	10.2262 mL	20.4524 mL
5 mM	0.409 mL	2.0452 mL	4.0905 mL
10 mM	0.2045 mL	1.0226 mL	2.0452 mL
50 mM	0.0409 mL	0.2045 mL	0.409 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. *Front Pharmacol.* 2021;12:636324.

Liu R, et al. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study. *BMC Gastroenterol.* 2021;21(1):398.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481